WWM
NBIX icon

Willingdon Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History

Willingdon Wealth Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-4
Closed – – 487
2019
Q3 		$0 Buy
+4
New +$374 ﹤0.01% 526

Other funds holding NBIX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Willingdon Wealth Management's NBIX Position: Q4 2019 in Review

Willingdon Wealth Management sold out of Neurocrine Biosciences (NBIX) in Q4 2019, closing a stake of 4 shares.

Willingdon Wealth Management first reported a position in NBIX in Q3 2019 and held it in 1 quarter. The position peaked at $0 in Q3 2019. 391 funds tracked by Wall St. Rank hold NBIX as of Q4 2019.

  • Willingdon Wealth Management reported no remaining Neurocrine Biosciences position as of Q4 2019 after selling out during the quarter.
  • Willingdon Wealth Management sold 4 Neurocrine Biosciences shares in Q4 2019.
  • Willingdon Wealth Management first reported a position in Neurocrine Biosciences in Q3 2019 and held it in 1 quarter.
  • Willingdon Wealth Management's Neurocrine Biosciences position peaked at $0 in Q3 2019.
  • 391 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2019.

Based on Willingdon Wealth Management's 13F filing for Q4 2019, filed 10 Feb 2020.